Evidence map›Paper›PMID 40726407›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Acidosis Forces Fatty Acid Uptake and Metabolism in Cancer Cells Regardless of Genotype.

Sébastien Ibanez, Maria Virginia Giolito, Sultan Al-Siyabi, Kristian Serafimov, Florine Laloux, Emeline Dierge, Léo Aubert, Céline Guilbaud, Selena Kaye, Paula Varon and 11 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Acidosis Forces Fatty Acid Uptake and Metabolism in Cancer Cells Regardless of Genotype.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sébastien IbanezPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Maria Virginia GiolitoPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Sultan Al-SiyabiPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Kristian SerafimovPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Florine LalouxPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Emeline DiergePole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Léo AubertPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Céline GuilbaudPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Selena KayePole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Paula VaronPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Dorothée MarchandPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Hanne VlieghePôle de Recherche en Physiopathologie de la Reproduction, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Emmanuel HermansGroup of Neuropharmacology, Institute of Neuroscience, UCLouvain, Brussels, B-1200, Belgium.
Caroline BouzinImaging Platform 2IP, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Davide BrusaCytoFlux-Flow Cytometry and Cell Sorting Platform, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Christiani Andrade AmorimPôle de Recherche en Physiopathologie de la Reproduction, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Barabara PachikianCenter of Investigation in Clinical Nutrition, UCLouvain, Louvain-la-Neuve, B-1348, Belgium.
Yvan LarondelleLouvain Institute of Biomolecular Science and Technology (LIBST), UCLouvain, Louvain-la-Neuve, B-1348, Belgium.
Cyril CorbetPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Chantal DessyPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.
Olivier FeronPole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, B-1200, Belgium.ORCID https://orcid.org/0000-0001-5360-0286

Funding

Fédération Wallonie-Bruxelles ARC 19/24-096Fondation contre le Cancer 2020-074Fondation contre le Cancer 2024-152Fonds De La Recherche Scientifique - FNRS EOS O002522FFonds De La Recherche Scientifique - FNRS PDR P.C006.22Fonds De La Recherche Scientifique - FNRS PDRT008719FWalloon excellence in life sciences and biotechnology X104022F
6 · The paper itself

Abstract

While proteins facilitate fatty acid (FA) partitioning into plasma membranes, movement between membrane leaflets occurs through a "flip-flop" mechanism. This study provides evidence that biological acidosis, as encountered in tumors and ischemic diseases, promotes FA protonation, thereby enhancing neutral, non-ionized FA uptake. This positions the altered lipid metabolism in acid-exposed cells as a consequence, rather than a cause, of preferential FA uptake. Cancer cell vulnerability, independent of their genetic background, directly stems from this paradigm shift, as detoxifying the overload of very long-chain FA (VLCFA) becomes highly dependent on peroxisomal activity. Inhibition of peroxisomal function in acid-exposed cancer cells leads to the rerouting of these fatty acids into triglycerides within lipid droplets, but also into phospholipids, contributing to membrane alterations, triggering ER stress, and ultimately supporting cytotoxicity. Using patient-derived tumor organoids and sera from human volunteers supplemented with polyunsaturated FA (PUFA), it is shown that inhibiting peroxisomal ACOX1 selectively kills acid-exposed cancer cells, an effect exacerbated by pharmacological stimulation of glycolysis. Similar acid-driven FA uptake is observed in endothelial cells and cardiac myocytes, opening new therapeutic avenues not only cancer but also cardiovascular diseases.

Indexed as

AcidosisFatty AcidsNeoplasmsCell Line, TumorGenotypeHumansLipid MetabolismPeroxisomesFatty Acidsacidosiscancerfatty acidlipid metabolismperoxisome

Identifiers

PMID40726407
PMCPMC12561199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.